Henoch-schönlein purpura following the first dose of covid-19 viral vector vaccine: A case report

34Citations
Citations of this article
52Readers
Mendeley users who have this article in their library.

Abstract

A 76 year-old female came to our observation one week after the vaccination with ChA-dOx1 nCoV-19 AZD1222 for the onset of purpuric rash on her gluteal and legs regions associated with coxalgia and episodes of macrohaematuria. Henoch-Schönlein purpura (HSP) was diagnosed on the basis of the revised criteria developed by the European League Against Rheumatism, the Paediatric Rheumatology International Trials Organization, and the Paediatric Rheumatology European Society (EULAR/PRINTO/PRES). HSP is a common IgA-mediated small vessel vasculitis, typical of childhood, that affects several systems and is characterized by a tetrad of dermatological, abdominal, joint, and renal manifestations. The Etiology of HSP is not completely understood, but it was observed following upper respiratory tract infections, medications, vaccinations, and malignancies. HSP has previously been reported following immunization with various vaccines, mostly within 12 weeks post, suggesting a possible correlation. To our knowledge, this is the first report of the possible association between COVID-19 ChAdOx1 nCoV-19 AZD1222 and the onset of HSP in a previously healthy woman. No similar cases were reported amongst 23.848 participants in the ChAdOx1 nCoV-19 AZD1222 trial.

Cite

CITATION STYLE

APA

Sirufo, M. M., Raggiunti, M., Magnanimi, L. M., Ginaldi, L., & De Martinis, M. (2021). Henoch-schönlein purpura following the first dose of covid-19 viral vector vaccine: A case report. Vaccines, 9(10). https://doi.org/10.3390/vaccines9101078

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free